Corient Private Wealth LLC Invests $274,000 in Inari Medical, Inc. (NASDAQ:NARI)

Corient Private Wealth LLC acquired a new stake in shares of Inari Medical, Inc. (NASDAQ:NARI) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,373 shares of the company’s stock, valued at approximately $274,000.

Several other large investors have also recently bought and sold shares of the company. Bamco Inc. NY boosted its position in shares of Inari Medical by 29.5% during the third quarter. Bamco Inc. NY now owns 1,006,129 shares of the company’s stock worth $41,493,000 after purchasing an additional 228,977 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Inari Medical during the 3rd quarter worth $9,008,000. Jennison Associates LLC lifted its holdings in Inari Medical by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after acquiring an additional 186,617 shares in the last quarter. Lisanti Capital Growth LLC acquired a new position in Inari Medical in the fourth quarter valued at about $3,969,000. Finally, Y Intercept Hong Kong Ltd increased its holdings in shares of Inari Medical by 316.7% in the third quarter. Y Intercept Hong Kong Ltd now owns 44,318 shares of the company’s stock worth $1,828,000 after acquiring an additional 33,682 shares in the last quarter. Institutional investors own 90.98% of the company’s stock.

Insider Activity at Inari Medical

In related news, Director William Hoffman sold 200,000 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the transaction, the director now directly owns 238,987 shares in the company, valued at approximately $14,451,543.89. The trade was a 45.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Piper Sandler lifted their price objective on Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a report on Tuesday, January 7th. Oppenheimer began coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price target on the stock. William Blair reissued a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Baird R W lowered shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $80.00 target price (up from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Inari Medical has a consensus rating of “Hold” and an average target price of $68.00.

Inari Medical Price Performance

Shares of NASDAQ:NARI opened at $79.97 on Tuesday. The company’s 50-day moving average price is $79.88 and its two-hundred day moving average price is $61.80. Inari Medical, Inc. has a one year low of $36.73 and a one year high of $79.99. The stock has a market capitalization of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.